跳转至内容
Merck

1561507

USP

磷酸伯安喹

United States Pharmacopeia (USP) Reference Standard

别名:

8-(4-氨基-1-甲基丁氨基)-6-甲氧基喹啉 二磷酸盐, 伯氨喹 二磷酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H21N3O · 2H3PO4
CAS号:
分子量:
455.34
Beilstein:
3812133
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

primaquine

製造商/商標名

USP

mp

205-206 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

OP(O)(O)=O.OP(O)(O)=O.COc1cc(NC(C)CCCN)c2ncccc2c1

InChI

1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)

InChI 密鑰

GJOHLWZHWQUKAU-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Primaquine phosphate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monograph such as Primaquine Phosphate Tablets.

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 3 Oral - Muta. 2 - Repr. 2

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Improving the radical cure of Plasmodium vivax malaria.
Ric N Price
The American journal of tropical medicine and hygiene, 91(1), 3-4 (2014-04-23)
Interactive medical case. A chilly fever.
Amanda J Redig et al.
The New England journal of medicine, 371(16), e24-e24 (2014-10-16)
N P Dhammika Nanayakkara et al.
Antimicrobial agents and chemotherapy, 58(8), 4737-4744 (2014-06-11)
Hematotoxicity in individuals genetically deficient in glucose-6-phosphate dehydrogenase (G6PD) activity is the major limitation of primaquine (PQ), the only antimalarial drug in clinical use for treatment of relapsing Plasmodium vivax malaria. PQ is currently clinically used in its racemic form.
Tamar E Carter et al.
The American journal of tropical medicine and hygiene, 91(2), 412-414 (2014-06-04)
Haiti is one of two remaining malaria-endemic countries in the Caribbean. To decrease malaria transmission in Haiti, primaquine was recently added to the malaria treatment public health policy. One limitation of primaquine is that, at certain doses, primaquine can cause
Stefanie C P Lopes et al.
The Journal of infectious diseases, 209(9), 1403-1407 (2014-01-15)
There is now a growing body of evidence that challenges the current view that Plasmodium vivax-infected erythrocyte (Pv-iE) are unable to sequester. Here we used ex vivo adhesion assays with Pv-iE before and after maturation to demonstrate a higher binding

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门